Skye Bioscience, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SKYE

Core Viewpoint - A class action lawsuit has been filed against Skye Bioscience, Inc. for alleged violations of the Securities Exchange Act, specifically related to misleading statements about the efficacy of its drug nimacimab [1][2]. Group 1: Lawsuit Details - The class period for the lawsuit is from November 4, 2024, to October 3, 2025, with a deadline for lead plaintiff appointments set for January 16, 2026 [2]. - The complaint alleges that Skye made false and misleading statements regarding the efficacy of nimacimab, which did not demonstrate the claimed effectiveness [2]. Group 2: Shareholder Participation - Shareholders who purchased shares during the class period are encouraged to contact the DJS Law Group for potential lead plaintiff appointments, although this is not required to participate in any recovery [2][3]. - Once registered, shareholders will be enrolled in a portfolio monitoring system to receive updates on the case's progress at no cost [3]. Group 3: DJS Law Group's Role - DJS Law Group specializes in securities class actions and corporate governance litigation, focusing on enhancing investor returns through advocacy [4]. - The firm represents large hedge funds and alternative asset managers, emphasizing the value of litigation claims as significant assets [4].